Search results for "GIST"

showing 10 items of 3463 documents

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success

2020

In this review, we summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. MCOs have been held in five different geographical regions including: a) Central Europe, b) Eastern Europe and Balkans, c) Baltic and Euroasia, d) Arab World and Southern European Countries and e) Latin America. More than 2.000 young oncologists have attended and more than 250 distinguished faculty members have actively participated. The program exposes students to sessions covering all major tumors ("big killers") and to spotlights updating information on various important cancers and related topics. Participants are able to present their own cl…

0301 basic medicineLatin Americans2720 HematologyLearning assessment610 Medicine & healthMedical Oncology03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesMedicineTumor boardHumansSocieties MedicalClinical OncologyOncologistsMedical educationbusiness.industryTeachingHematologyTest (assessment)Europe030104 developmental biologyOncologyEducation Medical Graduate030220 oncology & carcinogenesis10032 Clinic for Oncology and Hematology2730 OncologyClinical casebusiness
researchProduct

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

2018

Background & aims AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon-free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort. Methods A retrospective analysis of the DHC-R (Deutsches Hepatitis C-Register, German Hepatitis C-Registry) coh…

0301 basic medicineLedipasvirMalemedicine.medical_specialtySofosbuvirSustained Virologic ResponseHepatitis C virusMedizinHepacivirusmedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineGermanyRibavirinMedicineHumansClinical significanceRegistriesRetrospective StudiesHepatitisFluorenesHepatologybusiness.industryRibavirinvirus diseasesHepatitis CViral Loadmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologychemistryRNA Viral030211 gastroenterology & hepatologyBenzimidazolesFemaleSofosbuvirbusinessUridine MonophosphateViral loadmedicine.drug
researchProduct

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients.

2018

Abstract Eighty percent of hepatocellular carcinoma (HCC) cases occur after cirrhosis from various etiologies. The association between diet and cancer is well accepted, but the links with cirrhosis progression and HCC risk have been poorly investigated. However, we hypothesized that diet could be a modifiable preventive factor for HCC. Thus, the aim of our study was to explore the relationships between dietary factors and the risk of HCC in a population of cirrhotic patients. A total of 582 cirrhotic patients were studied: 401 without HCC (controls) and 181 with HCC (cases). These patients were recruited between 2008 and 2012 for the “CiRCE” case-control study conducted in six French univer…

0301 basic medicineLiver CirrhosisMale*Diet/adverse effectsCirrhosisEndocrinology Diabetes and MetabolismGastroenterologyFood groupchemistry.chemical_compound0302 clinical medicineEndocrinologyDiet and cancerRisk FactorsOdds RatioProspective StudiesProspective cohort study*Case-control studyeducation.field_of_studyNutrition and DieteticsLiver NeoplasmsMiddle Aged3. Good healthHepatocellular carcinomaFemale*Feeding Behavior*Hepatocellular carcinomaFranceLiver Neoplasms/etiology/*prevention and controlVitaminmedicine.medical_specialtyCarcinoma Hepatocellular*CirrhosisPopulation030209 endocrinology & metabolism*Diet03 medical and health sciencesHepatocellular/etiology/*prevention and controlInternal medicinemedicineDiabetes MellitusHumanseducationLiver Cirrhosis/complications/*diet therapyAged030109 nutrition & dieteticsbusiness.industryCarcinomaCase-control studyFeeding Behaviormedicine.diseaseDietLogistic ModelschemistryCase-Control StudiesbusinessEnergy Intake[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNutrition research (New York, N.Y.)
researchProduct

The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.

2017

Chronic hepatitis B (CHB) is characterized by hepatic inflammation that promotes progression to cirrhosis and predisposes to the development of hepatocellular carcinoma (HCC). Subtle interindividual genetic variation as well as viral and environmental factors interact to determine disease progression between individuals. Recently, the rs641738 membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) polymorphism was demonstrated to influence histological liver damage in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but no data are available for CHB. We evaluated rs641738 influence on disease severity in a cohort of 1,101 patients with CHB. Forty-two patien…

0301 basic medicineLiver CirrhosisMaleAlcoholic liver diseaseCirrhosisSex FactorSeverity of Illness IndexCohort StudiesGene FrequencyFibrosisNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseAge FactorProspective StudiesChronicMembrane ProteinMultivariate AnalysiAge FactorsHepatitis CSingle NucleotideMiddle AgedHepatitis BPrognosisHepatocellular carcinomaDisease ProgressionFemaleHumanAdultmedicine.medical_specialtyLogistic ModelPrognosiAcyltransferaseLiver CirrhosiAcetyltransferases; Acyltransferases; Adult; Age Factors; Cohort Studies; Confidence Intervals; Disease Progression; Female; Gene Frequency; Genetic Predisposition to Disease; Hepatitis B Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Polymorphism Single Nucleotide; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex FactorsPolymorphism Single NucleotideRisk Assessment03 medical and health sciencesHepatitis B ChronicSex FactorsSDG 3 - Good Health and Well-beingAcetyltransferasesInternal medicineAcetyltransferasemedicineConfidence IntervalsHumansGenetic Predisposition to DiseasePolymorphismHepatologybusiness.industryMembrane ProteinsHepatologymedicine.diseaseMinor allele frequencyProspective Studie030104 developmental biologyLogistic ModelsImmunologyMultivariate AnalysisCohort StudiebusinessConfidence IntervalAcyltransferasesHepatology (Baltimore, Md.)
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.

2017

BACKGROUND & AIMS The worldwide spread of obesity is leading to a dramatic increase in the prevalence of nonalcoholic fatty liver disease (NAFLD) and its complications. We aimed to evaluate both prevalence and factors associated with NAFLD in a general population in a Mediterranean area. METHODS We considered 890 consecutive individuals included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study (ISRCTN15840340). Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were measured with FibroScan. Participants were genotyped for PNPLA3 rs738409 and TM6SF2 rs58542926 variants. RESULTS The prevalence of NAFLD in the cohort was 48%. NAFL…

0301 basic medicineLiver CirrhosisMalesteatosigeneral populationGastroenterologySeverity of Illness Index0302 clinical medicinepatatin like phospholipase domain containing 3FibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceliver stiffness measurementeducation.field_of_studyMiddle Agedtransient elastographycontrolled attenuation parameterItalyLiverCohortElasticity Imaging Techniquestransmembrane 6 superfamily 2030211 gastroenterology & hepatologyFemalefibrosiAdultmedicine.medical_specialtyPopulationPopulationPolymorphism Single Nucleotide03 medical and health sciencesDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansObesityeducationstiffneAgedHepatologybusiness.industrynutritional and metabolic diseasesMembrane ProteinsLipasemedicine.diseaseObesitydigestive system diseases030104 developmental biologyLogistic ModelsTransient elastographybusinessTM6SF2Liver international : official journal of the International Association for the Study of the Liver
researchProduct

Protein supplement consumption is linked to time spent exercising and high-protein content foods: A multicentric observational study

2019

The main aim of this study is to analyze if protein supplement consumption and food patterns vary across three geographical regions and secondly to identify possible factors that increase the likelihood of ingesting protein supplements.A total of 916 responses from gym users of 3 countries (Italy, Turkey and UK) were entered for analysis. Questions were related to supplement consumption (protein and other supplements), food intake and training habits. A descriptive analysis, analysis of variance (ANOVA), and logistic regression were performed.No differences were found across groups regarding: prevalence of protein supplement consumption, typology of other ingested supplement and food intake…

0301 basic medicineLogistic regressionArticle03 medical and health sciences0302 clinical medicineEnvironmental healthPsychologylcsh:Social sciences (General)lcsh:Science (General)NutritionConsumption (economics)Settore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportiveMultidisciplinaryDescriptive statisticsHigh proteinFood PatternsCanned fishSettore MED/32 - AudiologiaSettore MED/18 - Chirurgia Generale030104 developmental biologylcsh:H1-99Observational studyAnalysis of varianceSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie030217 neurology & neurosurgerylcsh:Q1-390Heliyon
researchProduct

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1

2019

Long noncoding RNAs (lncRNAs) are emerging as key regulators of genetic and epigenetic networks, and their deregulation may underlie complex diseases, such as carcinogenesis. Several studies described lncRNA alterations in patients with solid tumors. In particular, HOTAIR upregulation has been associated with tumor aggressiveness, metastasis, and poor survival in gastrointestinal stromal tumor (GIST) patients. We analyzed expression levels of other lncRNAs, H19 and MALAT1, in FFPE tissue specimens from 40 surgically resected and metastatic GIST patients, using real-time PCR analysis. H19 and MALAT1 were both upregulated in 50% of GIST patients. MALAT1 lncRNA expression levels seem to be cor…

0301 basic medicineMALAT1long non coding RNAs H19 MALAT1Article SubjectGiSTbusiness.industryHOTAIRlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemedicine.disease_causelcsh:RC254-282Metastasis03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyDownregulation and upregulation030220 oncology & carcinogenesisCancer researchmedicineGastrointestinal stromal tumors (GISTs)Stromal tumorCarcinogenesisbusinessResearch ArticleJournal of Oncology
researchProduct

Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment.

2017

Background/Aim: Pediatric thyroid cancer (TC) is rare but its incidence is increasing. We analyzed incidence and characteristics of pediatric TC in Sicily and comparatively evaluated data from the volcanic and non-volcanic areas. Materials and Methods: All incident pediatric (0-19 years) TCs in Sicily between 2002-2009 were analyzed for the area of residence and compared to data for adults. Results: A total of 54 differentiated TCs (DTC) and nine medullary TCs were diagnosed in Sicily in children between 2002-2009. DTC age standardized rate for the world population (ASRw) was 0.8/105 in females and 0.2/105 in males, with a higher incidence in the volcanic area (ASRw=1.4/105 in females, 0.5/…

0301 basic medicineMaleCancer ResearchPapillaryPediatricsCohort Studies0302 clinical medicineRisk FactorsMedicineRegistriesChildThyroid cancerSicilygeography.geographical_feature_categoryThyroid cancer epidemiologyGeographyIncidence (epidemiology)IncidencePediatric ageGeneral MedicineOncology030220 oncology & carcinogenesisChild PreschoolEvaluated dataFemaleStandardized ratePediatric thyroid cancer; Thyroid cancer and volcanic environment; Thyroid cancer epidemiologyThyroid cancer and volcanic environmentAdolescentPediatric thyroid cancer; Thyroid cancer and volcanic environment; Thyroid cancer epidemiology; Adolescent; Carcinoma Papillary; Child; Child Preschool; Cohort Studies; Female; Geography; Humans; Incidence; Infant; Infant Newborn; Male; Pediatrics; Registries; Risk Factors; Sicily; Thyroid Neoplasms; Volcanic Eruptions; Young Adult; Oncology; Cancer ResearchVolcanic Eruptions03 medical and health sciencesYoung AdultArea of residenceHumansThyroid NeoplasmsPreschoolgeographybusiness.industryfungiCarcinomaInfant NewbornInfantmedicine.diseaseNewbornCarcinoma Papillary030104 developmental biologyVolcanoPediatric thyroid cancerbusinessDemographyAnticancer research
researchProduct